

Online Supplementary Material

Resource use and cost associated with cardiovascular, renal, bone and neuropsychiatric comorbidities in people with HIV in Spain. *JHEOR*. 2025;12(2):147-153. [doi:10.36469/jheor.2025.143019](https://doi.org/10.36469/jheor.2025.143019)

Figure S1: Model Schema

Table S1: Baseline Prevalence of Comorbidities

Table S2: Annual Incidence of Comorbidities (2024-2034)

Table S3: Sensitivity Analysis Parameters

Table S4: Cost per Year in the Current Scenario (Million Euros)

Table S5: Sensitivity Analysis Results (Person-Years)

Figure S2: Sensitivity Analysis Results (Costs)

This supplementary material has been provided by the authors to give readers additional information about their work.



Figure S1. Model Schema




Table S1. Baseline Prevalence of Comorbidities

Comorbidity	Prevalence Cohort <10 Years from Diagnosis (%)	Prevalence Cohort ≥10 Years from Diagnosis (%)
Cardiovascular	4.80	17.10
Renal	2.30	7.70
Bone	6.90	16.50
Neuropsychiatric	4.50	16.30

Table S2. Annual Incidence of Comorbidities (2024-2034)

Comorbidity	Incidence <10 Years from Diagnosis (%)		Incidence ≥10 Years from Diagnosis (%)	
	<50 y	≥ 50 y	<50 y	≥ 50 y
Cardiovascular	0.77	3.40	1.80	3.83
Renal	0.38	1.36	0.86	1.39
Bone	1.38	1.59	1.82	3.17
Neuropsychiatric	0.92	0.68	1.95	2.17

Table S3. Sensitivity Analysis Parameters

	Prevalence (%)	
	SA 1: Cohort With Diagnosis <10 y	SA 2: Cohort With Diagnosis ≥10 y
Cardiovascular	2.05	4.70
Renal	1.98	5.95
Bone	–	11.10
Neuropsychiatric	3.48	–

Abbreviation: SA, sensitivity analysis.

Table S4. Cost per Year in the Current Scenario


	Year	Cost in Million Euros (€)		
		Diagnosis < 10 y Ago	Diagnosis ≥ 10 y Ago	Total
Cardiovascular	0	12.93	70.26	83.19
	1	14.15	72.58	86.74
	2	15.20	80.38	95.58
	3	16.07	86.73	102.80
	4	16.80	91.80	108.60
	5	17.40	95.75	113.14
	6	17.87	98.72	116.59
	7	18.23	100.84	119.06
	8	18.49	102.21	120.70
	9	18.66	102.93	121.59
	10	18.76	103.09	121.85
Renal	0	7.78	39.75	47.53
	1	8.59	41.66	50.24
	2	9.27	45.43	54.71
	3	9.86	48.61	58.47
	4	10.35	51.24	61.60
	5	10.76	53.39	64.15
	6	11.09	55.10	66.19
	7	11.35	56.42	67.78
	8	11.55	57.39	68.95
	9	11.69	58.05	69.75
	10	11.78	58.43	70.22
Bone	0	11.78	42.98	54.77
	1	13.27	44.60	57.87
	2	14.54	48.42	62.96
	3	15.61	51.51	67.12
	4	16.50	53.98	70.48
	5	17.22	55.89	73.12
	6	17.81	57.31	75.12
	7	18.26	58.30	76.56
	8	18.60	58.91	77.51
	9	18.83	59.19	78.03
	10	18.97	59.19	78.16
Neuropsychiatric	0	14.85	82.07	96.92
	1	16.86	85.78	102.64
	2	18.58	89.52	108.10
	3	20.04	92.45	112.50
	4	21.28	94.67	115.94
	5	22.30	96.25	118.55
	6	23.14	97.26	120.40
	7	23.80	97.78	121.58
	8	24.32	97.86	122.18
	9	24.69	97.56	122.25
	10	24.95	96.92	121.87

Table S5. Sensitivity Analysis Results (Person-Years)

	Current Scenario (PY)	SA 1: CoRIS Prevalence (PY)	SA 1: Difference With Current Scenario* (PY)	SA 2: VACH Prevalence (PY)	SA 2: Difference With Current Scenario* (PY)
Cardiovascular	287 002	272 453	-14 549	198 113	-88 889
Renal	130 479	128 771	-1707	116 645	-13 834
Bone	293 297	–	–	253 682	-39 614
Neuropsychiatric	247 407	242 040	-5368	–	–

Abbreviations: CoRIS, Cohort of the Spanish HIV/AIDS Research Network; PY, person-years; SA, sensitivity analysis.

Figure S2. Sensitivity Analysis Results: Costs



Abbreviations: CoRIS, Cohort of the Spanish HIV/AIDS Research Network; PY, person-years; SA, sensitivity analysis.